Tiorfix Baby

Quick links

Choose a section

Quick links to important sections

Advertisements

Tiorfix Baby

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Tiorfix Baby

Quick Facts

Property Description
Active ingredient Racecadotril (Prodrug)
Form Powder/Granules for oral suspension (Sachet)
Pharmacological class Antisecretory Agent (NEP inhibitor)
Common use Reduction of watery stools in acute diarrhea
Origin Synthetic

Tiorfix Baby is a specialized, synthetic medication designed for the pediatric population to address acute diarrhea by controlling the underlying cause of excessive fluid secretion in the gut. The name "Baby" explicitly designates its target user group—infants and young children—and its formulation as a powder for oral suspension reflects this specific positioning. The drug is clinically recognized as an antisecretory agent, a modern pharmacological approach that distinguishes it from traditional anti-motility therapies.


What Type of Antidiarrheal Medicine is Tiorfix Baby?

The active substance in the preparation is Racecadotril, a prodrug that converts into its active metabolite, Thiorphan, upon administration. It belongs to the pharmacological class of neutral endopeptidase inhibitors (NEP inhibitors). The drug’s unique mechanism is highly selective: it blocks the enzyme responsible for breaking down the body's natural compounds in the digestive tract, which consequently reduces the abnormal flow of water into the intestines. Racecadotril provides an effective antisecretory effect without compromising the normal passage of contents through the gut. This mechanism works to reduce fluid loss while mitigating potential side effects related to slowed intestinal movement.


Composition and High-Level Purpose

Tiorfix Baby features Racecadotril as the single active ingredient, formulated specifically as a powder for oral suspension or granules in sachets. This specialized presentation is crucial for infants and young children, allowing the contents of the sachet to be easily mixed with food or water for simple, accurate administration. The medication's general purpose is to combat the primary physiological issue in acute diarrhea: fluid hypersecretion. By effectively decreasing the volume of the watery output, the drug assists in mitigating the risk of rapid fluid and electrolyte depletion—a critical concern in this patient population—which is the main benefit for the patient. The drug acts against hypersecretion in the small intestine.

Advertisements

What side effects are possible with Tiorfix Baby?

Possible side effects and safety information

This section outlines the adverse reactions and safety characteristics of the active substance, Racecadotril, as documented in official government regulatory sources, without providing clinical advice or usage instructions.


Documented Adverse Reactions and Frequency

Adverse reactions are classified by official regulatory bodies based on how frequently they have been reported. The side effects primarily involve the skin and subcutaneous tissue disorders and the nervous system.

Classification Example Reactions System-Organ Class
Common (1 to 10 in 100 users) Headache Nervous system disorders
Uncommon (1 to 10 in 1,000 users) Rash, Erythema Skin and subcutaneous tissue disorders
Uncommon (Pediatric Specific) Tonsillitis Infections and infestations

Serious Safety Considerations

The most clinically significant risks officially documented are those related to serious hypersensitivity. These include Angioedema (swelling of the face, lips, or tongue) and Severe Cutaneous Adverse Reactions (SCARs), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Anaphylactic shock. These severe events have a Frequency Not Known (cannot be estimated from available data) but are considered high-priority risks that may occur at any time during treatment.


Safety-Related Restrictions

Official prescribing information notes that caution is required in patients with severe renal or hepatic impairment due to limited clinical data. The medicine is contraindicated in individuals with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Furthermore, concomitant use with Angiotensin-Converting Enzyme (ACE) inhibitors may elevate the risk of Angioedema. The medication should not be used if the patient has fever or observes bloody or purulent stools.

Advertisements

Overdose and Emergency Response

The regulatory information concerning overdose for Tiorfix Baby (racecadotril) is highly specific, emphasizing the drug’s substantial safety margin. Official documentation states that no cases of overdose have been reported. Furthermore, clinical studies administering single doses of up to 2 grams of the active substance—an amount twenty times the typical therapeutic dose—to adults resulted in no described harmful effects or adverse clinical events. This information establishes the official threshold for exposure where no acute toxic effects were observed.

Overdose Profile Focus Official Regulatory Statement
Documented Manifestations No cases of overdose have been reported, and no harmful effects were described at doses 20 times the therapeutic level.
Antidote Information No specific antidote has been identified for the active substance.

In the event of a suspected or confirmed overdose, the official regulatory guidance mandates that management should follow recognised procedures for overdose. Therefore, seeking immediate medical attention is required for appropriate symptomatic and supportive care. Population-specific overdose data for infants and young children is not explicitly detailed in the overdose section; however, the instruction to follow recognised procedures ensures professional evaluation.

Advertisements

Therapeutic Uses of Tiorfix Baby

What Tiorfix Baby Treats: Main Uses and Benefits

Tiorfix Baby is commonly used to help with symptomatic relief in conditions presenting with acute episodes of watery diarrhea in the pediatric population, including infants and young children. The medicine is applied in addressing symptoms related to heightened physiological activity, such as excessive watery stools and high frequency, which are symptoms associated with acute or episodic changes.


Quick Fact: Relief for Watery Stools

Focus Description
Primary Symptom Domain Symptoms related to heightened physiological activity (watery stools)
Therapeutic Goal Managing the risk of rapid fluid and electrolyte depletion
Target Population Infants and Young Children

The medicine is relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support when needed. It is considered relevant for managing the risk of rapid fluid and electrolyte depletion (dehydration), which is a significant concern during episodes marked by increased physiological stress. This focus contributes to maintaining a sense of stability when symptoms are more noticeable, and may be part of symptomatic management when symptoms become temporarily overwhelming, helping to improve day-to-day comfort.

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Tiorfix Baby (Racecadotril) is strictly defined by regulatory authorities based on age and specific medical status.

Eligibility Scope

Category Eligibility Rule (Official Regulatory Position)
Approved Population Infants and children older than 3 months of age experiencing acute watery diarrhea.
Key Age Restriction Infants less than 3 months old must not be administered this product due to a lack of established clinical data.
Absolute Contraindications Patients with known hypersensitivity to racecadotril or any excipients, and individuals with rare hereditary problems of sugar intolerance (e.g., fructose intolerance).

Official Restrictions and Non-Eligibility

  • Children with any degree of renal (kidney) impairment or hepatic (liver) impairment must not be administered Tiorfix Baby, as data are insufficient in these patient populations.
  • Use is not recommended if the child has bloody or purulent stools or high fever, which may indicate an invasive bacterial infection.
  • The medicine should not be administered to pregnant or breastfeeding women due to the absence of adequate clinical studies.
  • It is not recommended for use in cases of chronic diarrhea or antibiotic-associated diarrhea as the product has not been tested in these specific conditions.

The regulatory profile strictly limits the use of Tiorfix Baby to the 3 month-old pediatric population with acute, non-complicated diarrhea, mandating exclusion for patients with specific comorbidities or inadequate safety data.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Description
Medicinal product categories with documented interactions Angiotensin-Converting Enzyme (ACE) Inhibitors; CYP450 enzyme substrates/inducers/inhibitors (low potential for interaction); Highly plasma protein-bound substances (low potential for interaction).
Specific interacting medicines (if explicitly listed) ACE Inhibitors (e.g., captopril, enalapril); Loperamide; Nifuroxazide; High Plasma Protein-Bound Substances (e.g., tolbutamide, warfarin, digoxin, phenytoin).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic interaction (increased risk of bradykinin-mediated angioedema); Pharmacokinetic non-interaction (no clinically relevant inhibition/induction of major CYP450 enzymes).
Interaction-related restrictions Contraindicated use in patients with a history of ACE inhibitor-induced angioedema.

Interaction Classifications (High-Level)

Category Description
Interaction severity classification (as defined in official documents) Contraindicated combination (based on specific patient history); Clinically non-significant pharmacokinetic interaction (with major metabolic enzymes).

Resulting Interaction Structure

The interaction profile is primarily defined by a specific pharmacodynamic restriction. Co-administration with ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors) may increase the risk of bradykinin-mediated angioedema. Based on this official risk, use of the medicine is contraindicated in patients with a prior history of angioedema caused by an ACE inhibitor.

Conversely, the medicine shows a low potential for pharmacokinetic interactions. Regulatory data confirms that the active metabolite does not clinically inhibit or induce major CYP450 enzymes (including CYP3A4, 2D6) or UGT enzymes. Furthermore, it does not modify the protein binding of highly bound active substances such as warfarin, digoxin, and phenytoin. The kinetics of the medicine are also not modified by co-administration with loperamide or nifuroxazide. Administration with food delays the time to maximum plasma concentration (Tmax) but does not change the overall exposure (bioavailability) of the drug.

Advertisements

Mechanism of Action

Protecting Natural Gut Regulators

The mechanism begins with the conversion of the prodrug, Racecadotril, into its active form, Thiorphan, which then acts as a specific inhibitor of the enzyme Neutral Endopeptidase (NEP) . This enzyme naturally breaks down endogenous enkephalins, which are endogenous peptides that modulate fluid and electrolyte transport across the intestinal epithelium. By blocking NEP, the drug increases the local concentration and prolongs the activity of these natural peptides. This molecular action engages the pathway that modulates transepithelial fluid and ion movement.


Targeted Reduction of Intestinal Hypersecretion

The protected enkephalins bind to and activate delta-opioid receptors on the intestinal cells, initiating a signaling cascade that reduces the intracellular concentration of cyclic AMP (cAMP) . Since high cAMP levels drive the secretion of chloride ions ( Cl^-) and water into the intestine, this reduction limits the signaling that drives excessive ion and fluid secretion. The mechanism results in an antisecretory effect due to the limitation of ion and fluid outflow, without altering normal intestinal motility.

Advertisements

Dosage and Administration Information

How to Use Tiorfix Baby (Racecadotril)

The usage of Tiorfix Baby is characterized by specific patterns for administration, dosage, and duration. The medication is delivered via the oral route only, using granules for oral suspension found in sachets. It is crucial that the administration of this medicine is always a complementary treatment used in conjunction with Oral Rehydration Solution (ORS).


Dosing and Preparation

Feature Official Usage Principle
Dosing Regimen 1.5 mg/ kg of body weight per dose, administered three times daily (TID).
Administration Timing Preferably administered at the beginning of the three main meals.
Preparation The granules must be mixed into food, water, or a feeding bottle, stirred well, and administered immediately.

Duration and Patient Restrictions

The treatment is restricted to short-term use and must not continue for longer than seven days. Administration should be discontinued as soon as the patient passes two normal stools. Use is limited to infants older than 3 months of age, as clinical data do not support use in younger infants or neonates. The administration protocol is designed to ensure precise, weight-dependent dosage and to enforce a time-limited course of therapy.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tiorfix Baby

The research evidence for Racecadotril, the active ingredient in Tiorfix Baby, was studied for its use as an adjunctive treatment in children receiving standard Oral Rehydration Solution (ORS). The foundational evidence is derived from numerous Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-analyses focused on conditions characterized by fluctuating or episodic manifestations of acute watery diarrhea in the pediatric population.

Study Outcomes Examined by Researchers

The clinical research primarily studies explored changes during the acute phase of the illness. Outcomes related to outcomes describing episodic or acute changes studies monitored included the duration of diarrhea (defined by researchers as the time until symptoms met criteria for resolution) and stool output/volume over the first 48 hours. Findings describe patterns observed in the studies that certain measurements related to symptom duration may be influenced when Racecadotril was observed in the study populations, though results are not uniform across all trials.

Evidence in Populations and Uncertainties

The evidence base research describes patterns primarily relevant to infants and young children generally aged 3 months up to 5 years, in both outpatient and hospitalized settings. It is important to note that the results apply only to the populations studied. Follow-up durations were limited to the acute illness period, and consequently, long-term effects are not fully established.

Authoritative systematic reviews suggest that the certainty of the evidence for certain effects remains moderate to low. This is often due to methodological heterogeneity across trials and findings being mixed or inconsistent for severe outcomes like the rate of rehydration failure. Data for certain groups remain insufficient, particularly for infants under three months of age.

Key Studies & References

  1. Racecadotril for childhood diarrhoea: meta-analysis from the WHO Global Research Programme on diarrhoeal diseases.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tiorfix Baby (FAQ)

Q: How quickly is Tiorfix Baby supposed to start working?

A: Official information indicates that the medicine's activity against the fluid-regulating enzyme begins within approximately 30 minutes after a dose. The peak effect of this enzyme blockage is typically reached about one to three hours after the product is administered.

Q: Is Tiorfix Baby the same as other diarrhea medicines like Loperamide or Pepto Bismol?

A: No, it works differently. Tiorfix Baby is an antisecretory agent, meaning its primary role is to reduce the excessive secretion of water and ions into the intestine. Regulatory information states that it does this without affecting the speed of the intestine's movement, which distinguishes it from traditional anti-motility drugs.

Q: Why is this medicine specifically called 'Baby'?

A: The name reflects its intended user group. According to official product monographs, Tiorfix Baby is formulated as granules for oral suspension, a dosage form that is specifically designed for ease of administration to infants and young children (generally aged 3 months up to 5 years).

Q: Are there any common foods that can interact with Tiorfix Baby?

A: Official documentation states that while taking the medicine with food may delay the time it takes to reach maximum activity, the overall amount of medicine the body absorbs (its bioavailability) is not affected. The medicine is generally given with food or water as described in the official instructions.

Q: Is it normal to see no change after the first dose?

A: The medicine's peak activity is achieved between one and three hours after dosing, and the treatment is typically given three times a day. Official instructions state that the treatment should continue until the patient has passed two normal stools, indicating that resolution may take time and is not always immediate.

Q: Is Tiorfix Baby safe for a child who has lactose intolerance?

A: The medicine is contraindicated (meaning its use is advised against) for patients with rare hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This is because the product contains lactose monohydrate as an excipient.

Q: What should I look for if I suspect an allergic reaction to Tiorfix Baby?

A: Official safety documents highlight the risk of serious hypersensitivity reactions. Signs to be aware of include Angioedema (swelling of the face, lips, or tongue, which may involve the throat) and other severe skin reactions. Use of the medicine is contraindicated if a patient has a known hypersensitivity to the ingredients.

Q: Does Tiorfix Baby cause constipation after the diarrhea stops?

A: In clinical trials, official reports indicate that the rate of post-treatment constipation was observed with the same frequency in those receiving the medicine as in those who received a placebo (an inactive substance).

Q: What happens if a dose of Tiorfix Baby is forgotten?

A: General caution is noted in official documents that a double dose should not be taken to make up for a forgotten dose; the recommendation is to continue treatment as scheduled.

Q: What does the research say about Tiorfix Baby's use in younger infants?

A: Official documents advise that the medicine is not recommended for infants under three months of age. This is because the clinical data and safety profile for this very young population are not considered sufficient or established.

Q: What is the difference between Tiorfix Baby and an Oral Rehydration Solution (ORS)?

A: Oral Rehydration Solution (ORS) is the essential primary treatment to replace the water and salts lost due to diarrhea. Tiorfix Baby is an adjunctive (complementary) treatment used alongside ORS; its function is to reduce the excessive fluid being secreted into the intestine.

Q: Can Tiorfix Baby be taken at the same time as fever reducers like paracetamol?

A: Official interaction studies suggest the medicine has a low potential for pharmacokinetic interactions, meaning it does not typically interfere with how the body processes most other medicines. There are no specific drug-drug interactions listed with acetaminophen (paracetamol).

Q: Is Tiorfix Baby available over the counter in all countries?

A: Official regulatory status for the active ingredient, Racecadotril, varies internationally. It may be available only by prescription in some regions, while in others, it has been granted over-the-counter (OTC) status, often with restrictions on pack size or indication.

Q: What specific ingredients, besides the main one, are in Tiorfix Baby?

A: The official product monograph lists several excipients (inactive ingredients) in the formulation. These typically include sugars like lactose monohydrate and sucrose, as well as other components like colloidal anhydrous silica and a flavor (such as apricot) to improve taste.

Q: Why do doctors sometimes prescribe Tiorfix Baby instead of antibiotics for diarrhea?

A: The medicine is a symptomatic treatment that reduces the watery output in acute diarrhea, which is suitable for many common causes. It is not an antibiotic, and official warnings state it is not recommended if the child has signs of an invasive bacterial infection, such as blood or pus in the stool.

Q: Does Tiorfix Baby have any impact on stomach pain or cramping?

A: Although it is not a direct pain reliever, official clinical literature has noted that treatment with the medicine has sometimes been associated with less abdominal distension and discomfort compared to placebo. Its primary action, however, is on fluid secretion.

Q: Can Tiorfix Baby be taken with food, or must it be on an empty stomach?

A: Official documentation indicates that it can be taken with food. It is often described as being administered at the beginning of the main meals. While food may delay the time it takes to reach maximum activity, it does not change the amount of medicine absorbed.

Q: Is Tiorfix Baby known to cause sleepiness or drowsiness?

A: No, official documentation states that the medicine's action is primarily peripheral (localized in the gut). It is designed not to affect the central nervous system and has not been shown to produce central nervous stimulant or sedative effects.

Q: Are there any specific warnings for children with kidney issues?

A: Official documents note that patients with severe renal (kidney) impairment or hepatic (liver) impairment require caution because clinical data in these groups are limited.

Q: Why is monitoring hydration important when using Tiorfix Baby?

A: Monitoring hydration is essential because Tiorfix Baby is a symptomatic treatment that must be used alongside Oral Rehydration Therapy (ORT). This ensures that the patient actively replaces the water and electrolytes lost from diarrhea, which is the necessary primary management step.

Q: Is the main active substance in Tiorfix Baby found naturally?

A: No, the active substance, Racecadotril, is classified as a synthetic compound. It functions by protecting the body's own naturally occurring peptides, called enkephalins, which are responsible for regulating fluid.

Q: Does Tiorfix Baby have a specific taste or smell that children dislike?

A: Clinical literature notes that the active substance itself can have an unpleasant taste. The pediatric granules are therefore typically formulated with flavouring agents, such as apricot, to make the product more acceptable to children.

Q: Can Tiorfix Baby be used to prevent diarrhea?

A: The official therapeutic indication is for the symptomatic treatment of acute diarrhea. The product is not studied for, or authorized for, the prophylactic (preventative) use of diarrhea.

Q: Is the medicine known to have any effects on the skin, like rashes?

A: Yes, official adverse reaction reports classify rash and erythema (skin redness) as uncommon side effects (may affect up to 1 in 100 people). More severe skin reactions are also reported at an unknown frequency.

Q: What does the term 'anti-secretory agent' mean in simple terms?

A: An anti-secretory agent is a medicine that reduces abnormal secretion in the body. In the context of Tiorfix Baby, this means it reduces the excessive flow of water and salts into the intestine, thereby lowering the volume of watery stool.

Q: Are there any specific studies regarding Tiorfix Baby's effectiveness in developing countries?

A: Official systematic reviews and clinical trials of the medicine have been widely published. This includes studies conducted in various geographic regions across the world, including countries in Africa and Asia, to establish its effectiveness in pediatric populations.

Q: What are the signs that Tiorfix Baby is working as expected?

A: The intended result of the medicine's anti-secretory action is a reduction in the total stool output and volume of watery stools. The official instruction is to discontinue the treatment once the patient passes two normal stools, which indicates the resolution of the acute episode.

Q: Can Tiorfix Baby be used for adult diarrhea?

A: The specific product, Tiorfix Baby granules for oral suspension, is officially indicated for infants and children. The active ingredient, Racecadotril, is generally available in different formulations and strengths for use in adults.

Q: What kind of diarrhea is Tiorfix Baby typically used for?

A: It is officially indicated for the symptomatic treatment of acute watery diarrhea in infants and children. It is not recommended for other types of diarrhea, such as those associated with high fever, blood, or pus in the stool.

Q: What are the most commonly reported side effects of Tiorfix Baby?

A: Based on official safety reporting, the only side effect listed as Common (meaning it may affect up to 1 in 10 people) is Headache. Other reactions, like rash and tonsillitis, are reported as less common.

Q: Can a child be allergic to Tiorfix Baby?

A: Yes, the product is contraindicated if a patient has a known hypersensitivity (allergic reaction) to the active substance or to any of the inactive ingredients. Severe allergic reactions, such as Angioedema, have been reported.

Q: Does Tiorfix Baby contain gluten or common allergens?

A: Official documentation does not list gluten as an ingredient. However, the formulation does contain lactose and sucrose, which are relevant for specific sugar intolerances. It is contraindicated for patients with certain hereditary sugar malabsorption issues.

Advertisements

How should Tiorfix Baby be stored and disposed of?

How to Store and Dispose of Tiorfix Baby

The storage and disposal of Tiorfix Baby (racecadotril) must strictly follow the conditions defined in official regulatory labeling.

Storage Requirements

This medicine does not require any special storage conditions, meaning it is stable at typical room temperature. The most important storage instruction is the Child Safety Mandate: Tiorfix Baby must be kept out of the sight and reach of children.

To ensure product quality, the medication must not be used after the expiry date (EXP) printed on the outer packaging.

Disposal Instructions

Official disposal rules classify this medicine as pharmaceutical waste. Do not throw away any medicines via wastewater or household waste. The mandatory procedure is to ask your pharmacist how to throw away medicines you no longer use. This ensures proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiorfix Baby found in:

A-Z Index: